FR0000120321 - Common Stock

Overall **OR** gets a fundamental rating of **6** out of 10. We evaluated **OR** against 13 industry peers in the **Personal Care Products** industry. **OR** gets an excellent profitability rating and is at the same time showing great financial health properties. **OR** is valied quite expensively at the moment, while it does show a decent growth rate. These ratings would make **OR** suitable for quality investing!

In the past year **OR** had a positive cash flow from operations.

Measured over the past 3 years, the **Average Return On Invested Capital** for **OR** is above the industry average of **12.00%**.

The last **Return On Invested Capital** (**16.57%**) for **OR** is above the 3 year average (**16.33%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 11.93% | ||

ROE | 21.27% | ||

ROIC | 16.57% |

ROA(3y)11.6%

ROA(5y)10.31%

ROE(3y)20.59%

ROE(5y)17.36%

ROIC(3y)16.33%

ROIC(5y)14.69%

With a decent **Operating Margin** value of **19.52%**, **OR** is doing good in the industry, outperforming **76.92%** of the companies in the same industry.

Looking at the **Gross Margin**, with a value of **73.86%**, **OR** belongs to the top of the industry, outperforming **92.31%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 19.52% | ||

PM (TTM) | 15.02% | ||

GM | 73.86% |

OM growth 3Y0.13%

OM growth 5Y0.44%

PM growth 3Y5.66%

PM growth 5Y0.76%

GM growth 3Y0.35%

GM growth 5Y0.29%

Compared to 1 year ago, **OR** has about the same amount of shares outstanding.

The number of shares outstanding for **OR** has been reduced compared to 5 years ago.

An Altman-Z score of **7.25** indicates that **OR** is not in any danger for bankruptcy at the moment.

Looking at the **Altman-Z score**, with a value of **7.25**, **OR** belongs to the top of the industry, outperforming **84.62%** of the companies in the same industry.

The Debt to FCF ratio of **OR** is **1.42**, which is an excellent value as it means it would take **OR**, only **1.42** years of fcf income to pay off all of its debts.

A Debt/Equity ratio of **0.21** indicates that **OR** is not too dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.21 | ||

Debt/FCF | 1.42 | ||

Altman-Z | 7.25 |

ROIC/WACC2.17

WACC7.65%

Looking at the **Current ratio**, with a value of **1.10**, **OR** is in line with its industry, outperforming **53.85%** of the companies in the same industry.

A Quick Ratio of **0.79** indicates that **OR** may have some problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.1 | ||

Quick Ratio | 0.79 |

The **Earnings Per Share** has been growing by **11.28%** on average over the past years. This is quite good.

The **Revenue** has been growing slightly by **7.64%** in the past year.

EPS 1Y (TTM)3.27%

EPS 3Y18.28%

EPS 5Y11.28%

EPS Q2Q%3.71%

Revenue 1Y (TTM)7.64%

Revenue growth 3Y13.73%

Revenue growth 5Y8.86%

Sales Q2Q%7.52%

Based on estimates for the next years, **OR** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **9.03%** on average per year.

The **Revenue** is expected to grow by **6.75%** on average over the next years.

EPS Next Y10.39%

EPS Next 2Y9.56%

EPS Next 3Y9.29%

EPS Next 5Y9.03%

Revenue Next Year6.37%

Revenue Next 2Y6.66%

Revenue Next 3Y6.67%

Revenue Next 5Y6.75%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

Based on the **Price/Earnings** ratio of **30.90**, the valuation of **OR** can be described as expensive.

The **Price/Forward Earnings** ratio is **26.28**, which means the current valuation is very expensive for **OR**.

61.54% of the companies in the same industry are cheaper than **OR**, based on the **Price/Forward Earnings** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 30.9 | ||

Fwd PE | 26.28 |

Based on the **Enterprise Value to EBITDA** ratio, **OR** is valued expensively inside the industry as 84.62% of the companies are valued cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 33.33 | ||

EV/EBITDA | 21.35 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

PEG (NY)2.97

PEG (5Y)2.74

EPS Next 2Y9.56%

EPS Next 3Y9.29%

With a **Yearly Dividend Yield** of **1.70%**, **OR** has a reasonable but not impressive dividend return.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.7% |

The dividend of **OR** is nicely growing with an annual growth rate of **11.70%**!

Dividend Growth(5Y)11.7%

Div Incr Years3

Div Non Decr Years3

The dividend of **OR** is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.

DP55.39%

EPS Next 2Y9.56%

EPS Next 3Y9.29%

**L'OREAL**

EPA:OR (8/2/2024, 7:00:00 PM)

**381.05**

**-6.8 (-1.75%) **

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap203.84B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.7% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 30.9 | ||

Fwd PE | 26.28 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)2.97

PEG (5Y)2.74

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 11.93% | ||

ROE | 21.27% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 19.52% | ||

PM (TTM) | 15.02% | ||

GM | 73.86% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.79

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.21 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.1 | ||

Quick Ratio | 0.79 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)3.27%

EPS 3Y18.28%

EPS 5Y

EPS Q2Q%

EPS Next Y10.39%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)7.64%

Revenue growth 3Y13.73%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y